Código QR (código de barras bidimensional)

CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies

In multiple myeloma (MM), the anti-CD38 monoclonal antibody Daratumumab has become essential in the therapeutic arsenal, although very few predictive factors of response to Daratumumab have been identified in clinical studies. We have prospectively collected biological data from 97 patients treated...

ver descrição completa

Na minha lista:
Principais autores: Djamila Chemlal, Camille Pochard, Valentin Jacquier, Angélique Bruyer, Ludovic Gabellier, Léa Fornero, Clément Vempère, Amélie Machura, Guilhem Requirand, Nicolas Robert, Caroline Bret, Guillaume Cartron, Laure Vincent, Hugues de Boussac, Jérôme Moreaux, Charles Herbaux
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis Group 2025-12-01
coleção:OncoImmunology
Assuntos:
Myeloma
immunotherapies
resistance
CD200
Acesso em linha:https://www.tandfonline.com/doi/10.1080/2162402X.2025.2532226
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados